Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may slow the growth of cancer cells. Oblimersen may increase the
effectiveness of thalidomide and dexamethasone by making cancer cells more sensitive to the
drugs.
PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and dexamethasone
with oblimersen in treating patients who have relapsed or refractory multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborators:
National Cancer Institute (NCI) University of Maryland Greenebaum Cancer Center